The FDA approved an oral formulation of Novo Nordisk’s GLP‑1 obesity drug, and the company is preparing a broad commercial launch. The approval makes Wegovy the first oral GLP‑1 cleared specifically for obesity and includes indications aligned with the injectable version, including cardiovascular risk reduction language. Regulators and payers will now weigh coverage and access pathways for a high‑demand, high‑visibility obesity medicine. Novo Nordisk reported plans for an aggressive launch strategy to scale distribution and physician uptake. The approval removes a key barrier to access for patients unwilling or unable to use injectables, and it may reshape competitive positioning across GLP‑1 oral and injectable portfolios. The FDA label and company guidance will be watched closely for prescribing restrictions and monitoring requirements. Clinicians and health systems will assess how the oral option alters treatment algorithms and market dynamics; payers will reassess coverage, utilization management, and expected budget impact as prescribers shift toward oral alternatives.